Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.31 |
| ▸ | GCGR | P47871 | 2/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988161 | 0.81 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL6982952 | 0.80 | MAPK14 (0.39) | PTGS2PTGS1GABRA2GABRB2MAPK13 | |
| SCHEMBL27581935 | 0.79 | — | — | |
| SCHEMBL8484619 | 0.63 | PTGS1 (0.39) | PTGS2PTGS1GABRA2GABRB2MAPK13 | |
| SCHEMBL27581621 | 0.62 | LCK (0.53) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6987088 | 0.62 | LCK (0.53) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7880443 | 0.62 | PSEN1 (0.44) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL8488021 | 0.61 | PTGS1 (0.45) | PTGS2PTGS1GABRA2GABRB2MAPK13 | |
| SCHEMBL27158612 | 0.59 | ADORA3 (0.40) | GABRA2GABRB2MAPK13GCGRMAPK12 | |
| SCHEMBL2849352 | 0.58 | MAPK14 (0.49) | MAPK13GCGRMAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| CN-1378544-A | Substituted azoles compounds | NOVARTIS AG (CH) | 2002-11-06 | — | — | CN | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | PTGS2 1162/4885PTGS1 129/4885GABRA2 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.